U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 Amendment No. 1
                                       to
                                  Form 10-KSB/A

   [X]   ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
         OF 1934 (FEE REQUIRED).

         For the fiscal year ended December 31, 1997.

   [ ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934 (NO FEE REQUIRED).

         For the transition period from __________ to __________.

                                        Commission file number   0-19827

                                  HYMEDIX, INC.
                 (Name of Small Business Issuer in Its Charter)

         Delaware                                           22-3279252
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                          Identification No.)

               2245 Route 130, Suite 104, Dayton, New Jersey 08810
          (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code:  (732) 274-2288

Securities registered under Section 12(b) of the Exchange Act:  None

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

                                 Yes X   No    
                                    ---     ---


                                     Page 1
<PAGE>


Check if disclosure of delinquent filers in response to Item 405 of Regulation
S-B is not contained in this form, and will not be contained, to the best of
registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. [X]

State registrant's revenues for its most recent fiscal year:    $1,783,331

The aggregate market value of the voting stock held by non-affiliates, based
upon the average of the bid and asked price of the Common Stock on March 26,
1998 as reported by The OTC Bulletin Board, was approximately 64,280 Shares
of Common Stock held by each officer and director and by each person who owns 5%
or more of the outstanding Common Stock have been excluded in that such persons
may be deemed to be affiliates for this purpose but not necessarily for other
purposes.

The number of shares of Common Stock outstanding as of March 26, 1998 was
5,713,500.

Transitional Small Business Disclosure Format (Check one):

                                                Yes       No   X
                                                    ---       ---  

                       Documents Incorporated by Reference

                                      None


                                     Page 2
<PAGE>


                                  HYMEDIX, INC.

                                      INDEX

                                                                      Page No.
PART III

     Item 10.     Executive Compensation                                  4
     Item 11.     Security Ownership of Certain Beneficial Owners         6
                  and Management
     Item 12.     Certain Relationships and Related Transactions          9
     Item 13.     Exhibits and Reports on Form 8-K                       10
     
SIGNATURES                                                               15


                                     Page 3
<PAGE>


                                    PART III



Item 10.      Executive Compensation.

The table below sets forth certain compensation information for the fiscal year
ended December 31, 1997, 1996 and 1995 with respect to HYMEDIX, Inc.'s
("HYMEDIX's" or the "Company's") Chief Executive Officer.

                                  HYMEDIX, INC.
                           Summary Compensation Table

<TABLE>
<CAPTION>

                                                                             Long-Term
                                                                            Compensation
                                                                            ------------
                                    Annual Compensation                        Awards
                                                                            ------------
                          ---------------------------------------            Securities
   Name and                                          Other Annual            Underlying
   Principal                                         Compensation              Options
   Position               Year          Salary($)        ($)(2)                (#)(1)
   ---------              ----          ---------    ------------            ----------
<S>                       <C>             <C>            <C>                   <C>
                          1997            121,377          0                      0
Joseph Y. Peng,           1996            113,615          0                   15,000
President and Chief
Executive Officer (3)(4)  1995             99,808          0                      0
</TABLE>

(1)  The option grants set forth hereof were granted by HYMEDIX to the named
     individuals issuable for shares of HYMEDIX Common Stock.

(2)  Represents car allowance for such executive officer.

(3)  During 1995, Mr. Peng was Chief Financial Officer of HYMEDIX.

(4)  Fiscal year 1997 compensation includes $41,538 accrued in fiscal year
     1996 and paid in fiscal year 1997.
     Fiscal year 1996 compensation includes $24,231 accrued in fiscal year 1995
     and paid in fiscal year 1996.
     Fiscal year 1995 compensation includes $27,692 accrued in fiscal year 1994
     and paid in fiscal year 1995.

       The Company has no pension, retirement, annuity, savings or similar
benefit plan for its executive officers.


                                     Page 4
<PAGE>


Executive Employment and Related Agreements

         Each of the Company's current and former employees and consultants
having access to its proprietary or technical information has executed a
confidentiality and invention assignment agreement with the Company.

         As of November, 1993, HYMEDIX entered into a Consulting Agreement with
Dr. Vladimir A. Stoy, a Company Director (the "Stoy Consulting Agreement"),
pursuant to which Dr. Stoy will serve on HYMEDIX's Board of Directors and render
certain consulting services to HYMEDIX. Under the Stoy Consulting Agreement, Dr.
Stoy is to be available to render services to HYMEDIX for at least 130 days per
year and is to receive consulting fees of $1,000 per diem for the first 52 days
of consulting rendered each year and $750 per diem for each additional day of
consulting, such consulting fees to be at least $52,000 per annum in the
aggregate, with certain consulting fees in the aggregate amount of $6,000 to be
credited against fees otherwise payable to Dr. Stoy as a member of HYMEDIX's
Scientific Advisory Board. Under the Stoy Consulting Agreement, Dr. Stoy has
agreed not to compete with HYMEDIX in any of the fields licensed to HYMEDIX
under the SKY License Agreement. See "Certain Transactions." The Stoy Consulting
Agreement is terminable by HYMEDIX for cause, upon Dr. Stoy's death or
disability or upon termination of the SKY License Agreement. The agreement may
be terminated by Dr. Stoy for cause or upon 30 days prior notice to HYMEDIX.


Stock Option Plans

         Amended and Restated 1991 Incentive and Non-Qualified Stock Option
Plan. On February 23, 1994, the Company's stockholders approved the adoption of
the Amended and Restated 1991 Incentive and Non-Qualified Stock Option Plan (the
"Stock Option Plan"). The Stock Option Plan is designed to qualify as an
incentive Stock Option Plans under Section 422 of the Internal Revenue Code of
1986, as amended. The Company may also award non-qualified stock options under
the Stock Option Plan. Pursuant to the terms of the Stock Option Plan, incentive
stock options may only be granted to management and other key employees of the
Company; non-qualified stock options may be granted to Directors, advisors and
consultants to the Company as well as employees. The Board of Directors has
appointed a Compensation Committee of the Board of Directors to administer the
Stock Option Plan, including the selection of the individuals to receive options
and the terms thereof. The Plan permits the grant of options to purchase up to
an aggregate of 500,000 shares of Common Stock.

         Under the Stock Option Plan, the exercise price of incentive stock
options must be not less than 100% (or 110% with respect to any optionee owning
more than 10% of the total combined voting power of all classes of stock of the
Company) of the fair market value of the Common Stock at the date of grant, and
the aggregate fair market value (determined at the time of grant) of shares
issuable pursuant to such options which first become exercisable in any calendar
year by an employee or officer, may not exceed $100,000. The term of such
options may not exceed ten years (except that with respect to any optionee who
owns more than 10% of the total combined voting power of all classes of stock of
the Company, the term may not exceed five years). The corresponding provisions
of any non-qualified stock options granted under the Stock Option Plan are not
similarly limited by the Stock Option Plan terms.

         As of March 31, 1998, options for the purchase of a total of 366,171
shares of Common Stock were outstanding under the Stock Option Plan (of which
421 were exercisable as of March 31, 1998) and options to purchase an
additional 133,829 shares remained available for grant under the Stock Option
Plan.


                                     Page 5
<PAGE>


         Director Stock Option Plan. On June 6, 1996, the Company's stockholders
approved the adoption of the Company's Director Stock Option Plan (the "Director
Plan"). The Director Plan is intended to provide nondiscretionary option grants
to independent Directors of the Company as follows: (1) to those persons already
serving on the Board and who are not employees, an option exercisable for 9,000
shares of the Company's Common Stock on the effective date of the Director Plan
and, for so long as service on the Board continues, an option of 2,000 shares of
the Company's Common Stock on each anniversary date thereof and (2) to those
persons joining the Board after the effective date of the Director Plan and who
are not employees, an option exercisable for 5,000 shares of the Company's
Common Stock on the date of election or appointment and, for so long as service
on the Board continues, an option for 2,000 shares of the Company's Common Stock
on each anniversary date of his or her joining the Company's Board, in each case
exercisable at fair market value and subject to certain provisions of
forfeiture. The Director Plan permits the grant of options to purchase up to an
aggregate of 50,000 shares of Common Stock, all of which were reserved for
grants under the Director Plan as of April 15, 1996.

Item 11. Security Ownership of Certain Beneficial Owners and Management.

         The following table sets forth certain information as of March 31, 1998
regarding the beneficial ownership of the Company's Common Stock by: (a) all
those known by the Company to be beneficial owners of more than 5% of its Common
Stock; (b) all Directors; (c) each of the executive officers of the Company
named in the Summary Compensation Table; and (d) all executive officers and
Directors of the Company as a group:


<TABLE>
<CAPTION>
       Name and Address                             Shares Beneficially
      of Beneficial Owner                               Owned(1)
      -------------------                       ---------------------------
                                                Number           Percentage
                                                ------           ----------
<S>                                             <C>                   <C>   
Kingston Technologies                           1,384,551             24.23%
 Limited Partnership (2)(3)

First Taiwan Investment                         2,658,423             46.53%
 Holding Inc. (4)(5)(6)

First Taiwan Venture                            2,658,423             46.53%
 Capital Inc. (4)(5)(7)

First Taiwan Investment and                     2,658,423             46.53%
 Development, Inc. (4)(5)(8)

Vladimir A. Stoy, Ph.D. (2)(3)                  1,390,180             23.94%

William G. Gridley, jr. (2)(3)                  1,452,065             25.01%

George P. Stoy (2)(3)                           1,404,437             24.19%
</TABLE>

                                     Page 6
<PAGE>


<TABLE>
<S>                                             <C>                   <C>   
Sheng-Hsiung Hsu (4)(5)(9)                      2,658,423             46.53%

Dr. Hsia-Fu Chao (4)(5)(10)                     2,658,423             46.53%

Shu-Jean Kuo Chou (4)(5)(11)                    2,658,423             46.53%

Michael K. Hsu (4)(5)(12)                       2,658,423             46.53%

John E. Bagalay Jr. (13)                           75,810              1.33%
 Boston University
 108 Bay State Road
 Boston, MA

Edward H. Jennings, Ph.D.                            ---                 *
 The Ohio State University
 154 W. 12th Street
 Columbus, OH

Joseph Y. Peng (14)                                37,514                *
 5 West Saddle River Road
 Waldwick, NJ

      All officers and Directors                4,211,813             72.54%
      as a group (12 persons)
</TABLE>

*     Less than one percent (1%).

(1)   Shares of Common Stock subject to options or warrants exercisable as of
      March 31, 1998 (or exercisable within 60 days after such date), are deemed
      outstanding for purposes of computing the percentage ownership of the
      person holding such option or warrant but are not outstanding for purposes
      of computing the percentage of any other person. Unless otherwise
      indicated in these footnotes, each stockholder has sole voting and
      investment power with respect to the shares beneficially owned.

(2)   Includes shares owned of record by Kingston Technologies Limited
      Partnership ("KTLP"). The general partners of KTLP include Vladimir A.
      Stoy, William G. Gridley, jr., George P. Stoy (each a Director of the
      Company) and Oak II, Inc., a corporation controlled by such Directors.
      Each of Vladimir A. Stoy, William G. Gridley, jr., and George P. Stoy
      exercises shares voting and investment power with respect to the shares of
      Common Stock of the Company held by KTLP and disclaims beneficial
      ownership of such shares except to the extent of his partnership interest
      in KTLP. Also gives effect to the exercise by Research Corporation
      Technologies, Inc., a Delaware nonprofit corporation ("RCT") and a
      stockholder of HYMEDIX, of its right to require KTLP to transfer and
      assign without further consideration, that number of shares of HYMEDIX
      Common Stock (166,271 shares) to make RCT's total holding of HYMEDIX
      Common Stock equal to 5% of HYMEDIX's outstanding Common Stock on a
      modified fully diluted basis (excluding shares reserved for issuance upon
      exercise of options granted under the HYMEDIX Stock Option Plan and
      conversion of HYMEDIX Series A Redeemable Preferred Stock) upon the
      effective date of the Company's Registration Statement on Form SB-2
      (effective August 12, 1995).

(3)   The business address of each of these persons is c/o HYMEDIX, Inc., 2245
      Route 130, Dayton, New Jersey 08810.

(4)   The business address of each of these persons is 13th Floor, 563 Chung
      Hsiao East Road, Section 4, Taipei, Taiwan 10516.


                                     Page 7
<PAGE>


(5)   Consists of the following:
<TABLE>

     <S>                                                                                        <C>

     *   shares owned of record by First Taiwan Investment Holding Inc. ("FTIHI")                 607,245
     *   shares owned of record by First Taiwan Venture Capital Inc. ("FTVC")                   2,150,158
     *   shares owned of record by First Taiwan Investment and                                  2,559,343
         Development, Inc. ("FTIDI")
                                                                                                ---------
     Total                                                                                      5,316,746
</TABLE>


Based on a Schedule 13D dated as of February 23, 1994 filed by FTIHI, FTVC,
FTIDI and Dr. Chao, such persons may be deem to form collectively a "group" and
each of such persons may be deemed to share voting power with each other with
regard to the foregoing shares. Dr. Chao, in his capacity as Chairman of FTIHI,
may also be deemed to share dispositive power over the shares of Common Stock
owned of record by or issuable to FTIHI.

(6)   FTIHI disclaims beneficial ownership as to 607,345 of such shares.

(7)   FTVC disclaims beneficial ownership as to 2,150,158 of such shares.

(8)   FTIDI disclaims beneficial ownership as to 2,559,343 of such shares.

(9)   Mr. Hsu is Chairman of FTVC. Mr. Hsu disclaims beneficial ownership of all
      such shares, except to the extent of his investment interest therein.

(10) Dr. Chao is Chairman of FTIHI. Dr. Chao disclaims beneficial ownership
     of all such shares, except to the extent of his investment interest 
     therein.

(11)  Ms. Chou is a Director of FTIHI. Ms. Chou disclaims beneficial ownership
      of all such shares, except to the extent of her investment interest
      therein.

(12)  Mr. Hsu is a Director of FTVC and until June 1995, was Executive
      Vice-President of each of FTIHI, FTVC and FTIDI. Mr. Hsu disclaims
      beneficial ownership of all such shares, except to the extent of his
      investment interest therein.

(13)  Mr. Bagalay is Managing Director of the Community Development Fund of
      Boston University. Mr. Bagalay disclaims beneficial ownership of all such
      shares. On September 19, 1997, Mr. John E. Bagalay Jr. replaced Mr. Golden
      as a director of the Company.

(14)  Includes 37,514 shares of Common Stock that Mr. Peng has the right to
      acquire upon the exercise of stock options.


                                     Page 8
<PAGE>


Item 12. Certain Relationships and Related Transactions.

              In April 1996, the Company issued convertible bonds in the
aggregate principal amount of approximately $981,000 (the "June Bonds") pursuant
to a Convertible Bond Purchase Agreement effective February 27, 1996, by and
among the Company, HYMEDIX International, First Taiwan Investment and
Development, Inc. and the Purchasers (as defined therein). The June Bonds bear
interest at a rate of 7% per annum and matured (after being extended) on
December 31, 1997. The June Bonds are convertible in whole or in part at any
time prior to payment or prepayment into one thousand (1,000) shares of common
stock of the Company for each one thousand dollars ($1,000) of principal amount
outstanding. Interest on the June Bonds is payable at maturity or upon
prepayment or conversion thereof.




                                    Page 9

<PAGE>


Item 13.          Exhibits and Reports on Form 8-K.

                           (a)      Exhibits.

Exhibit No.                Description
----------                 -----------

2.1       Amended and Restated Agreement of Merger and Plan of Reorganization,
          dated as of January 24, 1994 by and among Servtex International Inc.,
          Kingston Technologies, Inc., KTI Acquisition Corp. and certain
          affiliates of Servtex International Inc., filed pursuant to Rule 14a-6
          as Exhibit F to Proxy Statement of the Registrant (then Servtex
          International Inc.), dated February 12, 1994, and incorporated by
          reference herein.

2.2       Agreement of Merger, dated as of February 23, 1994 by and between 
          Servtex International Inc. and HYMEDIX, Inc., filed pursuant to Rule
          14a-6 as Exhibit A to Proxy Statement of the Registrant (then Servtex
          International Inc.), dated February 12, 1994, and incorporated by
          reference herein.

3.1       Certificate of Incorporation, filed pursuant to Rule 14a-6 as Exhibit
          B to Proxy Statement of the Registrant (then Servtex International
          Inc.), dated February 12, 1994, and incorporated by reference herein.

3.2       Certificate of Designation, Preference and Rights of Series A 
          Redeemable Preferred Stock, filed as Exhibit (2) to Form 8-K, dated
          February 23, 1994, of the Registrant and incorporated by reference
          herein.

3.3       By-Laws of the Registrant, filed pursuant to Rule 14a-6 as Exhibit C
          to Proxy Statement of the Registrant (then Servtex International
          Inc.), dated February 12, 1994, and incorporated by reference herein.

4.1*      Specimen Certificate of the Registrant's Common Stock, $.001 par
          value.

10.1*     Form of the Underwriter's Warrant issued to First Flushing Securities,
          Inc. as a broker's fee for negotiating the merger of KTI Acquisition
          Corp., a Delaware corporation and wholly-owned subsidiary of the
          Registrant with and into HYMEDIX International.

10.2**    Option and License Agreement dated November 7, 1986 by and between
          HYMEDIX International and ORC, as amended by Amendment Number 1 to 
          Option and License Agreement dated January 9, 1987.

10.3*     Promissory Note, dated January 9, 1987, made by HYMEDIX International
          to the order of ORC, for $500,000.


                                    Page 10


<PAGE>


10.4*     Indenture of Lease dated July 7, 1987 by and between Fresh Ponds
          Associates and HYMEDIX International, as amended by First Amendment to
          Lease, dated September 13, 1993, Second Amendment to Lease, dated
          September 15, 1993, and Third Amendment to Lease, dated January 15,
          1994; and the related Installment Promissory Note, dated October 1,
          1993, made by HYMEDIX International to the order of Fresh Ponds
          Associates for $404,300.90.

10.5*     Promissory Note, dated September 29, 1987, made by HYMEDIX 
          International to the order of ORC, for $1,000,000.

10.6**    Agreement, dated December 22, 1988, by and between Kingston Hydrogels
          Limited Partnership and LIPO Chemicals, Inc., as amended by Amendment
          No. 1, effective June 1, 1990 and as further amended by Amendment
          Agreement, dated June 14, 1990.

10.7*     Loan and Security Agreement, dated October 30, 1989, by and between
          HYMEDIX International and Pilkington Visioncare, Inc. ("PVI").

10.8*     Promissory Note in the amount of $1,000,000, dated October 30, 1989,
          by HYMEDIX International, in favor of PVI

10.9*     Assignment of Patent, dated October 30, 1989 by HYMEDIX International
          in favor of PVI. 10.10** License and Supply Agreement, dated October
          30, 1989, between HYMEDIX International and PVI, along with Addendum
          thereto dated July 10, 1991.

10.11*    Contribution Agreement, dated August 7, 1990, by and between Kingston
          Technologies Limited Partnership ("KTLP") and HYMEDIX International.

10.12*    Royalty Assignment Agreement, effective August 8, 1990, by and between
          HYMEDIX International and Research Corporation Technologies, Inc. 
          ("RCT").

10.13*    Assignment of Patents, dated August 8, 1990, by KTLP in favor of 
          HYMEDIX International.

10.14*    Form of Amended and Restated Warrant to Purchase Common Stock, dated
          February 23, 1994, delivered to Cheung Hok Sau.

10.15*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to the Trustees of Boston
          University.

10.16*    Right to Purchase Agreement, dated June 30, 1992, between HYMEDIX
          International and Lipo Chemicals, Inc.


                                    Page 11

<PAGE>


10.17*    License Agreement, dated June 30, 1992, between HYMEDIX International
          and Lipo Chemicals, Inc.

10.18*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to Synreal Corporation N.V.

10.19*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to Azreal Corporation N.V.

10.20*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to Dr. Hsia Fu Chao.

10.21     Amended and Restated 1991 Incentive and Non-Qualified Stock Option 
          Plan, filed pursuant to Rule 14a-6 as Exhibit E to Proxy Statement of
          the Registrant (then Servtex International Inc.), dated February 12,
          1994, and incorporated by reference herein.

10.22*    Employment Agreement, dated April 3, 1992, by and between HYMEDIX
          International and Alan L. Hershey, as amended by Agreement, dated
          January 4, 1993.

10.23*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to First Taiwan Investment
          Holding Inc.

10.24*    Registration Rights Agreement, dated May 28, 1993, by and between
          HYMEDIX International and the Trustees of Boston University.

10.25*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to the Trustees of Boston
          University.

10.26*    Form of Amended and Restated Common Stock Purchase Warrant, dated
          February 23, 1994, made by the Registrant to First Taiwan Investment 
          and Development Inc.

10.27*    Amended and Restated Registration Rights Agreement, dated February 23,
          1994, by and among RCT, First Taiwan Investment Holding Inc. and First
          Taiwan Venture Capital Inc.

                                    Page 12


<PAGE>


10.28**   Marketing and Distribution Agreement, dated July 30, 1993, by and
          between HYMEDIX International and Brady Medical Products, Co.

10.29*    Evaluation Agreement, dated December 1, 1993, by and between HYMEDIX
          International and Alcon Laboratories, Inc.

10.30*    Capital Contribution Agreement, dated February 23, 1994, by and 
          between the Registrant and RCT. 

10.31*    Demand Registration Rights Agreement, dated February 23, 1994, by and 
          between the Registrant RCT.

10.32*    Option to Wall Street Group.

10.33*    Redeemable Common Stock Purchase Warrant, dated February 23, 1994,
          made by the Registrant to First Taiwan Investment Holding Inc.

10.34*    Form of Warrant issued to Selling Stockholders (Domestic) in the
          private placements which closed February, 1994.

10.35*    Form of Warrant issued to Selling Stockholders (International) in the
          private placements which closed February, 1994.

10.36**   Development Services and Licensing Agreement, dated December 20, 1991,
          between HYMEDIX International and W. L. Gore and Associates, Inc.

10.37*    Joint Venture Agreement, dated May 31, 1994, by and among the 
          Registrant, Beijing General Pharmaceutical Corp., First Taiwan
          Investment Banking Group and Technological Innovation Corporation of
          China.

10.38***  Agreement, dated November 29, 1994, by and between HYMEDIX
          International and Bausch & Lomb. 

10.39***  Director Stock Option Plan, effective as of May 31, 1994. 

10.40**** Development Services and Licensing Agreement, dated December 20, 1991,
          between HYMEDIX International and W. L. Gore and Associates, Inc.

10.41**** Distribution, Kno-How Transfer, Licensing and Manufacturing and
          Supply Agreement dated August 21, 1995, by and between HYMEDIX
          International, Inc. and Europa Magnetics Corporation.


                                    Page 13


<PAGE>


10.42#    Master Terms and Conditions For Purchase Orders dated September 19,
          1995, by and between Home Shopping Club, Inc. and HYMEDIX 
          International, Inc.

10.43##   Convertible Bond Purchase Agreement, effective February 27, 1996, by
          and among the Company, HYMEDIX International, First Taiwan Investment
          and Development, Inc., and the Purchasers (as defined therein).

10.44##   Convertible Bond Purchase Agreement, effective March 5, 1996, by and
          among the Company, HYMEDIX International, and Su Chen Huang.

10.45###  Security Agreement dated as of August 8, 1996, by and among the 
          Company and the Bondholder Representative (as defined therein).

10.46     Restated Agreement between HYMEDIX International, Inc. and ProCyte
          Corporation dated as of November 20, 1997.

21*       Subsidiaries of the Registrant.

27        Financial Data Schedule.
-----------------------

*         Previously filed as an Exhibit to the Registrant's Form SB-2
          Registration Statement (No. 33-78638) originally filed on May 5, 1994
          and incorporated herein by reference.

**        Previously filed (and Confidential Treatment requested pursuant to
          Rule 406 under the Securities Act) as an Exhibit to the Registrant's
          Form SB-2 Registration Statement (No. 33-78638) originally filed on
          May 5, 1994 and incorporated herein by reference.

***       Previously filed as an Exhibit to the Registrant's Form 10-KSB
          originally filed April 17, 1995.

****      Previously filed (and Confidential Treatment requested pursuant to
          Rule 24-b2 under the Securities Exchange Act of 1934) as an Exhibit to
          the Registrant's Amendment No. 1 to Form 10-KSB/A originally filed 
          April 30, 1995.

****      Previously filed as an Exhibit to the Registrant's Form 10-QSB
          originally filed November 15, 1995.

#         Previously filed as an Exhibit to the Registrant's Form 10-KSB
          originally filed March 30, 1996

##        Previously filed as an Exhibit to the Registrant's Form 10-QSB 
          originally filed May 15, 1996.

###       Previously filed as an Exhibit to the Registrant's Form 10-QSB 
          originally filed November 13, 1996.

(b)       Reports on Form 8-K. No reports on Form 8-K were filed during the
          fourth quarter of 1997.


                                     Page 14


<PAGE>


                                   SIGNATURES


              In accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                             HYMEDIX, INC.
                             (Registrant)


Date: April 30, 1997         By:  /s/ Charles K. Kiment, Ph.D.
                                  -----------------------------
                                      Charles K. Kiment, Ph.D.
                                      President (Principal Executive Officer)



Date: April 30, 1997         By:  /s/ William G. Gridley, Jr.
                                  ---------------------------
                                      William G. Gridley, Jr.
                                      Chairman, Chief Financial Officer
                                      (Principal Financial Officer and
                                      Principal Accounting Officer)

                                     Page 15